[Translation]

October 23, 2026

MEDIPAL HOLDINGS CORPORATION
Representative: Kuniaki Imagawa, Representative Director, President and CEO
Code number: 7459 (Prime Market, Tokyo Stock Exchange)
Contact: Toshiyuki Ikeuchi,
Executive Officer, Head of Corporate Communications Department,
Corporate Planning Division
Tel: +81-3-3517-5171

Notice Regarding Decision on Matters Concerning Acquisition of Treasury Stock and Cancellation of Treasury Stock

(Acquisition of Treasury Stock Pursuant to the Provisions of the Articles of Incorporation Pursuant to the Provisions of Article 459, Paragraph 1 of the Companies Act and Cancellation of Treasury Stock Pursuant to the Provisions of Article 178 of the Companies Act)

At a meeting of its Board of Directors held on October 23, 2026, MEDIPAL HOLDINGS CORPORATION (the "Company") resolved matters related to acquisition of treasury stock pursuant to Article 459, Paragraph 1 of the Companies Act and the Company's Articles of Incorporation. And the Company resolved to cancel the treasury stock to be acquired through this resolution pursuant to Article 178 of the Companies Act. Details follow below.

1. Reasons for the acquisition and cancellation of treasury stock

The Company regards the distribution of profits to its shareholders as one of its highest management priorities, and its basic policy is to carry out "acquisitions and cancellations of treasury stock" flexibly for purposes of improving capital efficiency and further enhancing shareholder returns, while comprehensively assessing the Company's funding needs. Based on this policy, the Company has decided to carry out an acquisition and cancellation of treasury stock in order to further improve capital efficiency through shareholder returns by using the proceeds from the sale of investment securities described in the "Notice Regarding Recording of Gain on Sale of Investment Securities (Extraordinary Income)" and the "Notice Regarding Revision of Full-Year Consolidated Financial Forecasts" announced today, among other funds.

2. Details of the matters concerning the acquisition

(1)	Class of shares to be acquired	Common stock
(2)	Total number of shares to be acquired	Up to 4,000,000 shares (2.0% of the total number of common stock issued (excluding treasury stock))
(3)	Total acquisition cost	Up to 10 billion
(4)	Period of acquisition	From November 6, 2026 to March 31, 2027
(5)	Method of acquisition	Market buying on the Tokyo Stock Exchange

3. Details of the matters concerning the cancellation

(1)	Class of shares to be cancelled	Common stock
(2)	Total number of shares to be cancelled	The number corresponding to all of the treasury stock acquired through 2 above
(3)	Scheduled date	Implemented by March 31, 2027 after completion of the treasury stock acquired through 2 above.

Reference

Status of Treasury Stock Holding (as of September 30, 2026)

Total number of shares outstanding (excluding treasury stock)	204,698,231 shares
Total number of treasury shares	11,276,811 shares

# # #

The English version of this document is a translation of the Japanese original and is provided for informational purposes only. While reasonable efforts have been made to provide an accurate translation, no liability is assumed by MEDIPAL HOLDINGS CORPORATION for any errors, omissions, or ambiguities in the translation. If there are any inconsistencies or conflicts between the English version and the Japanese original, the Japanese original shall prevail.